Trial Profile
NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Bevacizumab (Primary) ; Brachyury peptide vaccine (Primary) ; Capecitabine (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Inbakicept (Primary) ; Omega-3-acid ethyl esters (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors NantKwest
- 27 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
- 08 Jun 2017 New trial record